Directory · ONC Oncology · Immunotherapy
Four ways to pay for the same line. Sort by insured markup to see where the hospital actually makes money.
| SKU | Hospital buy | Cash | Medicaid | Medicare | Insured | Insured − cash |
|---|---|---|---|---|---|---|
| Bevacizumab (Avastin-class) dose | $3,600 | $5,900 | $3,300 | $3,900 | $8,100 | $2,200 |
| Trastuzumab (Herceptin-class) dose | $4,200 | $6,800 | $3,800 | $4,500 | $9,200 | $2,400 |
| Nivolumab (Opdivo) dose | $9,800 | $12,800 | $9,000 | $10,500 | $15,000 | $2,200 |
| Pembrolizumab (Keytruda) dose | $11,500 | $14,500 | $10,500 | $12,200 | $16,800 | $2,300 |
Cash modeled Other payers modeled See evidence.